About Stemcis
Stemcis is a company based in Illkirch-graffenstaden (France) founded in 2008 by Franck Festy. Stemcis operates in a competitive market with competitors including Standard Bariatrics, Zeltiq, CoolSculpting, Nitinote Surgical and Modius Health, among others.
- Headquarter Illkirch-graffenstaden, France
- Founders Franck Festy
- SectorsHealthcare
- Email••••••••
- Website stemcis.com
- Social LinkedIn X
- Latest Funding Round$55.11K (USD), Grant
Aug 2019
- InvestorsEuropean Union
& 1 more
Funding Insights of Stemcis
- Total Rounds 2
- Last Round Grant — $55,105
- First Round $56,002
(May 2019)
- Investors Count 2
All 2 funding rounds of Stemcis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2019 | $55,105 | Grant | – | – | |
| May 2019 | $56,002 | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Stemcis
Stemcis has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | – | eicfund.eu | Brussels, Belgium | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Stemcis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Stemcis
1 people are tracked at Stemcis (1 in leadership).
| Name | Role | Group |
|---|---|---|
Franck Festy | Founder | Leadership |
Complete people profiles for Stemcis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Stemcis
3 dated milestones of Stemcis across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Stemcis is founded.
- Funding First funding round of $56K.
- Funding Latest funding round, Grant, of $55K.
Competitors of Stemcis
Stemcis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Standard Bariatrics, Zeltiq, CoolSculpting, Nitinote Surgical and Modius Health, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| standardbariatrics.com | 2014 | Cincinnati, United States | $35.5M | 34 | Medical devices for obesity surgical treatment are provided. | |
| zeltiq.com | 2005 | Pleasanton, United States | $70.42M | – | Controlled cooling technology is developed for non-surgical fat reduction. | |
| coolsculpting.com | 2005 | Pleasanton, United States | – | 82 | Non-surgical fat reduction is achieved through controlled-cooling technology. | |
| nitinotesurgical.com | 2014 | Ramat Gan, Israel | $26.1M | – | Non-surgical bariatric solutions for obesity are developed. | |
| modiushealth.com | 2017 | Belfast, United Kingdom | $1.59M | 21 | Non-invasive vestibular stimulation device for weight loss is offered. | |
| liposonix.com | 1999 | Hayward, United States | $37.94M | 6,139 | Non-surgical and non-invasive treatment to eliminate unwanted fat around waistline | |
| pandamed.cn | 2017 | Changzhou, China | $15.45M | – | Non-invasive devices for obesity and diabetes treatment are developed. | |
| hourglasstech.com | 2007 | Redwood, United States | – | – | Weight-loss solutions are developed via incision-free transoral procedures. | |
| ultrashape.com | 2002 | Irvine, United States | $15M | – | Non-invasive fat cell destruction for body contouring | |
| cabochoninc.com | 2005 | Menlo Park, United States | $14.79M | – | Delivers an ultrasound system for disrupting subcutaneous tissue in medical applications. |
Detailed competitors of Stemcis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Similar companies to Stemcis
10 companies that operate in the same segment as Stemcis (Metabolic Diseases), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 | |
Developer of cortisol modulators for the treatment of various diseases | 1998 | Menlo Park, California, United States | – | USD 761.41 M | 500 | |
Developer of therapies for the treatment of endocrine-related diseases and cancers | 2008 | San Diego, California, United States | USD 103.5 M | USD 1.04 M | 437 | |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | 2009 | Cambridge, Massachusetts, United States | USD 685 M | – | 81 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Solutions for biomarker discovery and diagnostic testing are provided. | 2000 | Morrisville, United States | USD 165.87 M | – | – | |
Therapeutics for gastrointestinal, cardio-renal, and metabolic diseases are developed. | 2007 | Fremont, California, United States | USD 61.1 M | USD 407.32 M | 395 | |
Biologics are developed for cardio-metabolic and liver diseases. | 2007 | San Francisco, California, United States | USD 358.87 M | USD 330.53 M | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Stemcis
Stemcis was founded in 2008 and raised its 1st funding round 11 years after it was founded.
Stemcis is headquartered in Illkirch-graffenstaden, France. It is registered at Illkirch-graffenstaden, Bas-rhin, France.
Stemcis was established in 2008 in Illkirch-Graffenstaden, France, as a provider of fat transfer kits within the medical devices sector. Kits are manufactured for applications in reconstructive surgery, orthopedic surgery, gynecological surgery, and dermatology. Operations focus on supporting these specialties through specialized equipment, with distribution centered in Europe. The company was founded by Franck Festy.
Stemcis's top competitors include Nitinote Surgical, CoolSculpting and Standard Bariatrics.
Stemcis has 2 investors. Key investors include European Union, and EIC Fund.